{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T05:04:50Z","timestamp":1648616690643},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.leukres.2013.08.013","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T01:45:45Z","timestamp":1378345545000},"page":"1436-1437","source":"Crossref","is-referenced-by-count":0,"title":["The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.08.013_bib0005","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.08.013_bib0010","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0015","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","article-title":"European treatment and outcome study (EUTOS) score for chronic myeloid leukemia still requires more confirmation","volume":"29","author":"Marin","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.08.013_bib0020","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood-2012-01-402511","article-title":"The EUTOS score aims to support clinical decision-making","volume":"119","author":"Hoffmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0025","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","article-title":"EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience","volume":"119","author":"Jabbour","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0030","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.leukres.2012.05.011","article-title":"The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"issue":"March","key":"10.1016\/j.leukres.2013.08.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1179\/1607845412Y.0000000071","article-title":"EUTOS CML prognostic scoring system predicts ELN-based event-free survival better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate","author":"Uz","year":"2013","journal-title":"Hematology"},{"issue":"June","key":"10.1016\/j.leukres.2013.08.013_bib0040","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","author":"Hoffmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.08.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2794.2794","volume":"120","author":"Yahng","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3758.3758","article-title":"The EUTOS score is highly predictive for clinical outcome and survival in Asian patients with early chronic phase chronic myeloid leukemia treated with imatinib","volume":"120","author":"Than","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0055","first-page":"454","article-title":"The EUTOS high-risk population differs substantially from the EURO score high-risk group; the EUTOS score predicts molecular response in chronic phase CML patients: results of the German CML-Study IV","volume":"97","author":"Saussele","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.08.013_bib0060","first-page":"76","article-title":"EUTOS score is predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with nilotinib-based regimens","volume":"97","author":"Castagnetti","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.08.013_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1681.1681","article-title":"EUTOS score is predictive of event-free survival, but not for progression-free and overall survival in patients with early chronic phase chronic myeloid leukemia treated with imatinib: a single institution experience","volume":"120","author":"Pagnano","year":"2012","journal-title":"Blood"},{"issue":"July","key":"10.1016\/j.leukres.2013.08.013_bib0070","article-title":"Tyrosine kinase inhibitor usage, treatment outcome and prognostic scores in CML: report from the population-based Swedish CML registry","author":"Hoglund","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.013_bib0075","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2013.07.037","article-title":"EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukemia","volume":"37","author":"Tiribelli","year":"2013","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T05:55:14Z","timestamp":1596434114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0145212613002956"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.08.013","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}